Elan announces US approval for MS drug

Elan and Biogen Idec announced today the US Food and Drug Administration (FDA) has approved Tysabri, formerly referred to as Antegren, as treatment for multiple sclerosis.

"Tysabri is a significant breakthrough for patients with MS," said Kelly Martin, president and chief executive officer, Elan.